Theranos Inc said on Monday it would stay out of the blood-testing business for at least two years in exchange for reduced penalties from federal health authorities.
The settlement resolves all outstanding legal and regulatory proceedings between Centers for Medicare & Medicaid Services (CMS) and the company, Theranos said.
